Boehringer Ingelheim strikes Chinese production alliance
This article was originally published in Scrip
Boehringer Ingelheimhas entered an alliance with the Chinese chemicals manufacturer Hisoarto supply pharmaceutical intermediates to the private German firm. Boehringer Ingelheim will incorporate these into active pharmaceutical ingredients for processing by its global production network. As part of the tie-up, Hisoar will invest in dedicated facilities at a new site in Chuannan which is scheduled to start early next year, and will receive know-how and technical support from its partner. The listed Chinese firm, based in Taizhou, Zhejiang province, had sales of around Yuan1 billion ($146.4 million) last year.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.